Wedbush Cuts Axcella Health's Price Target to $7 From $10 on Termination of AXA1665/OHE Trial; Outperform Rating Kept
6:55AM ET 5/27/2022 MT NewswiresAxcella Health (AXLA) has an average rating of outperform and price targets ranging from $7 to $19, according to analysts polled by Capital IQ. (MT...